Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?

Research output: Contribution to journalReview article

Abstract

Risk of brain metastases (BM) affects a remarkable number of non-small cell lung cancer (NSCLC) patients, impacting on their quality of life (QoL) and prognosis. While tyrosine-kinase inhibitors (TKIs) showed interesting intracranial control rates in oncogene-addicted NSCLC, BM still represent an unmet need for the counterpart without driver gene mutations. For these patients, new treatment options include anti-angiogenic drugs and immune-checkpoint inhibitors, possibly combined with standard chemotherapy, even though the benefit on BM has not been clearly defined. A multidisciplinary team including neurosurgeons, medical and radiation oncologists is needed in order to integrate systemic and loco-regional strategies at the right time point. Ad-hoc designed clinical trials are slowly emerging for previously treated patients with uncontrolled BM. The aim of this review is to offer a detailed and updated picture of possible approaches for non oncogene-addicted NSCLC patients having BM, in order to support clinicians in their daily practice.

Original languageEnglish
Pages (from-to)19-29
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume128
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
Oncogenes
Therapeutics
Angiogenesis Inhibitors
Brain Neoplasms
Protein-Tyrosine Kinases
Quality of Life
Clinical Trials
Drug Therapy
Mutation
Genes

Keywords

  • Antineoplastic Agents/therapeutic use
  • Brain Neoplasms/drug therapy
  • Carcinoma, Non-Small-Cell Lung/drug therapy
  • Humans
  • Lung Neoplasms/drug therapy
  • Mutation
  • Neoplasm Proteins/genetics
  • Oncogenes
  • Prognosis
  • Quality of Life

Cite this

@article{a09272c673734d5b832f3544ca1beff9,
title = "Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?",
abstract = "Risk of brain metastases (BM) affects a remarkable number of non-small cell lung cancer (NSCLC) patients, impacting on their quality of life (QoL) and prognosis. While tyrosine-kinase inhibitors (TKIs) showed interesting intracranial control rates in oncogene-addicted NSCLC, BM still represent an unmet need for the counterpart without driver gene mutations. For these patients, new treatment options include anti-angiogenic drugs and immune-checkpoint inhibitors, possibly combined with standard chemotherapy, even though the benefit on BM has not been clearly defined. A multidisciplinary team including neurosurgeons, medical and radiation oncologists is needed in order to integrate systemic and loco-regional strategies at the right time point. Ad-hoc designed clinical trials are slowly emerging for previously treated patients with uncontrolled BM. The aim of this review is to offer a detailed and updated picture of possible approaches for non oncogene-addicted NSCLC patients having BM, in order to support clinicians in their daily practice.",
keywords = "Antineoplastic Agents/therapeutic use, Brain Neoplasms/drug therapy, Carcinoma, Non-Small-Cell Lung/drug therapy, Humans, Lung Neoplasms/drug therapy, Mutation, Neoplasm Proteins/genetics, Oncogenes, Prognosis, Quality of Life",
author = "Stefano Frega and Laura Bonanno and Valentina Guarneri and Pierfranco Conte and Giulia Pasello",
note = "Copyright {\circledC} 2018 Elsevier B.V. All rights reserved.",
year = "2018",
month = "8",
doi = "10.1016/j.critrevonc.2018.05.013",
language = "English",
volume = "128",
pages = "19--29",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC)

T2 - Towards a less dismal future?

AU - Frega, Stefano

AU - Bonanno, Laura

AU - Guarneri, Valentina

AU - Conte, Pierfranco

AU - Pasello, Giulia

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2018/8

Y1 - 2018/8

N2 - Risk of brain metastases (BM) affects a remarkable number of non-small cell lung cancer (NSCLC) patients, impacting on their quality of life (QoL) and prognosis. While tyrosine-kinase inhibitors (TKIs) showed interesting intracranial control rates in oncogene-addicted NSCLC, BM still represent an unmet need for the counterpart without driver gene mutations. For these patients, new treatment options include anti-angiogenic drugs and immune-checkpoint inhibitors, possibly combined with standard chemotherapy, even though the benefit on BM has not been clearly defined. A multidisciplinary team including neurosurgeons, medical and radiation oncologists is needed in order to integrate systemic and loco-regional strategies at the right time point. Ad-hoc designed clinical trials are slowly emerging for previously treated patients with uncontrolled BM. The aim of this review is to offer a detailed and updated picture of possible approaches for non oncogene-addicted NSCLC patients having BM, in order to support clinicians in their daily practice.

AB - Risk of brain metastases (BM) affects a remarkable number of non-small cell lung cancer (NSCLC) patients, impacting on their quality of life (QoL) and prognosis. While tyrosine-kinase inhibitors (TKIs) showed interesting intracranial control rates in oncogene-addicted NSCLC, BM still represent an unmet need for the counterpart without driver gene mutations. For these patients, new treatment options include anti-angiogenic drugs and immune-checkpoint inhibitors, possibly combined with standard chemotherapy, even though the benefit on BM has not been clearly defined. A multidisciplinary team including neurosurgeons, medical and radiation oncologists is needed in order to integrate systemic and loco-regional strategies at the right time point. Ad-hoc designed clinical trials are slowly emerging for previously treated patients with uncontrolled BM. The aim of this review is to offer a detailed and updated picture of possible approaches for non oncogene-addicted NSCLC patients having BM, in order to support clinicians in their daily practice.

KW - Antineoplastic Agents/therapeutic use

KW - Brain Neoplasms/drug therapy

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Humans

KW - Lung Neoplasms/drug therapy

KW - Mutation

KW - Neoplasm Proteins/genetics

KW - Oncogenes

KW - Prognosis

KW - Quality of Life

U2 - 10.1016/j.critrevonc.2018.05.013

DO - 10.1016/j.critrevonc.2018.05.013

M3 - Review article

C2 - 29958628

VL - 128

SP - 19

EP - 29

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -